PCV108 Analysis of Outpatient Utilization and Costs of Antithrombotic Drugs in Poland – Implications for Pharmaceutical Pricing and Reimbursement Policy  by Bochenek, T. & Nizankowski, R.
acceptance of stroke prophylactic treatment. Interestingly, no single patients char-
acteristics changed the fact that AF patients were willing to accept a non-zero risks
of bleeding in exchange for prevention of disabling strokes.
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OBJECTIVES: To assess item analysis and dimensional validity of a new question-
naire developed to measure Satisfaction with medical care in patients with atrial
fibrillation, in order to accomplish item reduction. METHODS: The initial instru-
ment was composed by 37 items, arranged in 6 dimensions: 1- Efficacy (4 items), 2-
Ease and convenience (7 items), 3- Impact on daily activities (11 items), 4- Satisfac-
tion with medical care (6 items), 5- Medication undesired effects (6 items), and 6-
Overall satisfaction (4 items). Items and dimensions where extracted from review-
ing previous English instruments, 3 focus groups with chronic patients, and a panel
composed by 8 experts. Additionally 3 Visual Analog Scales (VAS) measuring Qual-
ity of Life, Effectiveness and Overall Satisfaction were applied. A convenience sam-
ple of 118 patients was used. Classic psychometric theory item analysis tech-
niques, exploratory factor and confirmatory factor analysis, test-retest and
correlation with VAS scales were used. RESULTS: The questionnaire was reduced
in length to 25 items, but the Impact dimension had to be divided in 2 dimensions:
Treatment inconvenience and Treatment Control. The reduced version presents
an overall Cronbach alpha of 0.861, with acceptable dimensional reliabilities (0.764-
0.908). Individual dimensions were well formed and correlated in different degrees,
being the dimension of Satisfaction with medical care the most independent one.
Test-retest correlations were high (0.784-0.965) and correlations with VAS scales
were meaningful. CONCLUSIONS: The 25-item questionnaire shows good reliabil-
ity and validity to assess satisfaction with medical care in patients with atrial
fibrillation. Further research is needed to examine if the questionnaire could be
generalized to different populations of patients with atrial fibrillation.
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OBJECTIVES: To describe demographical and medical characteristics of patients
treated with bi- or multi- antihypertensive therapies and to outline the link be-
tween therapeutic scheme, blood pressure control and patients co morbidities.
METHODS: A retrospective study was undertaken, based on the IMS Lifelink Elec-
tronic Medical Records database (Disease Analyzer), investigating age, gender,
blood pressure control and co morbidities according to the number and type of
associated antihypertensive therapies. RESULTS:A total of 13,618 patients, treated
by bi- or multi- antihypertensive therapies and for whom blood pressure levels
were available have been included in a 2008 study cohort (mean age  66.8, 48%
men). Respectively 39% and 58% of patients had a controlled blood pressure de-
pending on the threshold of the control (140/90 or 140/90), showing the im-
portance of the precise threshold in real-life. Respectively 1.5% and 0.3% of patients
had a blood pressure of over 160/100 and over 180/110. Significantly more patients
(p 0.05) have a controlled blood pressure under tri-therapy (41.6%/64.2% accord-
ing to the two previous thresholds) rather than under bi-therapy (37.9%/57.8%), but
no control difference is seen in patients treated by tri-therapy vs 4 or more. 59.4%
of patients have at least one cardiovascular, renal or diabetic co morbidity; a sta-
tistical link has been shown between the patient number of co morbidities and the
number of associated antihypertensive drugs in the treatment scheme.
CONCLUSIONS:The number of antihypertensive associated in a treatment scheme
increases with the patient co morbidity level. Despite the use of bi- or multi-ther-
apies, Sixty-one percent of patients who are being prescribed several antihyper-
tensive drugs do not have a controlled blood pressure (140/90); prescribing 4 or
more associated antihypertensive does not seem to increase the percentage of
controlled patients.
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OBJECTIVES: Disease definitions can evolve over time, and may be influenced by
the prevailing evidence base/understanding of the condition. Without a common
definition, significant scope exists for unanticipated impact on the health care
system and patients. We investigated this through assessment of primary non-
familial hypercholesterolaemia (PN-FH) in UK adults. METHODS: The 2007 NICE
Technology Appraisal of ezetimibe reported prevalence of PN-FH from two differ-
ent sources: 1) a 1999 publication reporting prevalence at 4.2%, based on a defini-
tion that PN-FH was “responsible for all cholesterol levels above the 95th percentile not
accounted for by a familial cause”; and 2) a 2003 article, reporting a range of 20-80%,
using a contemporary definition of PN-FH: a cholesterol level above a desirable/
recommended level, where familial and secondary causes have been excluded. We
used the older definition (4.2%) and lower bound of the range (20%) to estimate the
prevalence of PN-FH in UK adults. Simvastatin 40mg costs and Heart Protection
Study (HPS) results were used to estimate drug acquisition costs and number of
events prevented. RESULTS: At prevalence rates of 4.2% vs. 20%, 2.1m or 9.8m UK
adults have PN-FH. Accounting only for those diagnosed and requiring treatment
(30% of the population), the 1999 definition (4.2%) estimates 618,940 patients re-
quiring medication vs. 2,947,332 using the lower bound of the modern definition
(20%). The respective 5-year (mean follow-up in HPS) drug acquisition costs would
vary from £48.0m to £228.6m, and be expected to prevent 9,414 or 44,826 vascular
deaths, and 33,301 or 158,575 major vascular events (including 7,241 or 34,481
non-fatal MI’s and 8,022 or 38,201 non-fatal strokes). CONCLUSIONS: The impor-
tance of an accurate and contemporary definition of the condition under investi-
gation is paramount. Alternative rates available to NICE are associated with differ-
ences in 5-year drug cost of at least £180m, over 35,000 fewer vascular deaths and
125,000 fewer vascular events.
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OBJECTIVES: Egypt has long been trying to reform health care reimbursement
mechanisms. Currently, health care out-of-pocket expenditure in Egypt is almost
72%, with over 30% of total health care expenditure (THE) dedicated to medica-
tions1. At the same time, hypertension is becoming one of the main killers of
Egyptian adults. With an inefficient national scheme for financial protection
against chronic illnesses, anti-hypertensive medications are becoming a burden
for the Egyptian household budget. This research aims to examine factors affecting
affordability of anti-hypertensive medications in Egypt under current reimburse-
ment systems. METHODS: This research will use anti-hypertensive drugs sales
data as a proxy to identify the pattern of usage of antihypertensive drugs in differ-
ent regions of Egypt, under the different reimbursement systems (including out-
of-pocket). A trend (if any) will be drawn over time, to identify the impact of chang-
ing reimbursement policies, and the increase of medication prices on anti-
hypertensive drugs usage. For this purpose, we will look into sales/ dispensing data
from main health care providers; Ministry of Health & Population (MoHP), Health
Insurance Organization (HIO), and retail pharmacies’ sales data in the different
regions of Egypt. As well as demographic characteristics, health care services de-
livery models in each region, and the average annual income of individuals. Dif-
ferences between the different regions of Egypt, & factors affecting them, shall also
be highlighted. RESULTS: Weak and fragmented health insurance system, leads to
a high out-of-pocket drug expenditure, affecting affordability of, & subsequently
access to, anti-hypertensive medications. CONCLUSIONS: Efficient drug reim-
bursement systems should be improved to achieve better patient access to chronic
illnesses’ medication.
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OBJECTIVES: In May 2012, generic atorvastatin has become available in Belgium.
This study examines the impact of market entry of generic atorvastatin on Belgian
statin market and on cost-effectiveness of statin therapy. METHODS: Using IMS
Health data, the Belgian 2000-2011 statin market was analyzed in terms of total
expenditure, annual price of statin treatment, and number of patients. Also, a
simulation analysis projected market shares in the Belgian statin market from 2012
to 2015 following market entry of generic atorvastatin. This analysis was based on
three scenarios regarding the number of patients taking specific statins. Savings
associated with an atorvastatin price reduction of 50%-70% were calculated. A
literature review of economic evaluations was conducted to assess the cost-effec-
tiveness of generic atorvastatin. RESULTS: Statin expenditure more than doubled
from €113 million in 2000 to €285 million in 2011, mainly as a result of higher
expenditure on atorvastatin and rosuvastatin. Although the number of patients
treated with simvastatin increased by nearly 800% during 2000-2011, the resulting
increase in expenditure was partially offset by price reductions due to generic
competition and a simvastatin tender. The simulation analysis indicated that ator-
vastatin will become the dominant product in the Belgian statin market (market
share by expenditure of 47%-66% by 2015). Annual savings were projected to attain
€108.6-€153.7 million for a 50% reduction in the atorvastatin price and €152.0-€215.2
million for a 70% price reduction. The literature suggests that generic atorvastatin
is cost-effective as compared to simvastatin and becomes more cost-effective at
higher daily doses. The limited evidence about the cost-effectiveness of rosuvas-
tatin as compared with generic atorvastatin is inconclusive. CONCLUSIONS: Ge-
neric atorvastatin is cost-effective as compared to simvastatin, is projected to be-
come the dominant product in the Belgian statin market and is expected to
generate substantial savings to health care payers.
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OBJECTIVES: Pharmacotherapy is a major cost driver in venous thromboembolism
(VTE) treatment. Analyses of drug utilization and impact of pharmaceutical policy
are impeded by complicated rules of reimbursement, accessibility of data, changes
of prices and reference prices. The goal of this study was to critically assess utili-
zation and costs of reimbursed low-molecular weight heparins (LMWH) and vita-
min K antagonists (VKA) used on outpatient basis in Poland. METHODS: Reim-
bursement records of Silesian Provincial Division of National Health Fund (NHF)
were searched for detailed data on consumption of LMWH and VKA (FY 2009; about
4.646.000 insurees). Perspectives of public payer and patient were applied.
RESULTS: Market of antithrombotics was dominated by LMWH (97% of value, 98%
of reimbursement, 85% of packages number). Reimbursement constituted 94% of
LMWH value and 73% of VKA value. Daily cost of VTE pharmacotherapy with
LMWH was higher than with VKA (234 times for NHF, 42 times for patients). Within
groups of both LMWH and VKA reimbursement of daily doses of particular drugs
was changing in reverse manner than level of patient co-payment. Using warfarin
instead of acenocoumarol was more expensive for NHF by 147%, while for patients
cheaper by 25%. Using enoxaparin instead of nadroparin was for NHF more expen-
sive by 29%, but for patients less expensive by 15%. Using dalteparin instead of
nadroparin was even more expensive for NHF (by 46%), while for patients even
more cheap (by 23%). CONCLUSIONS: Market of reimbursed antithrombotic drugs
was dominated by LMWH. Pharmaceutical policy in Poland was not promoting
usage of less expensive therapeutic options within groups of LMWH and VKA.
Current implementation of new reimbursement law should be accompanied by
careful monitoring of impact, which it brings for rationalization of health policy.
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OBJECTIVES: Antithrombotic therapy with oral anticoagulants (vitamin K antago-
nists, VKAs) or antiplatelets (APs) is used to reduce stroke risk in patients with atrial
fibrillation (AF). This study reports on real-life prescription of VKAs and persistence
rates amongst AF patients in France and Spain. METHODS: A multicentre, retro-
spective, observational study was conducted using 2008–9 data from Longitudinal
Patient Databases (LPD©, Cegedim) of 1,200 and 300 general practitioners in France
and Spain, respectively. Patients with a diagnosis of AF during the study were
included and were considered to be receiving VKAs if they had 1 prescription
during the one-year follow-up. Persistence was defined as continuous use with
periods of 60 days interruption allowed. Persistence was assessed in newly diag-
nosed AF patients. RESULTS: In total, 11,355 and 2,924 AF patients were identified
in France and Spain, respectively. In France, VKAs were prescribed to 64% of pa-
tients (54% VKA only, 9% VKAAP) and 32% of eligible patients (CHADS2 stroke risk
score 2) did not receive anticoagulation. 15% of patients received no antithrom-
botic therapy. VKA persistence was 64% and 45% at 6 and 12 months. In Spain,
VKAs were prescribed to 52% of patients (44% VKA only, 8% VKAAP); 41% of
eligible patients did not receive anticoagulation. 16% of patients received no anti-
thrombotic therapy. VKA persistence was 60% and 38% at 6 and 12 months. In
France, univariate analyses showed anaemia, number of co-medications, hyper-
tension, BMI 25–30 kg/m2, age 75–84 years and age 85 years to be significant
negative predictors of persistence (p0.036 for all); prior myocardial infarction
(p0.079) was a non-significant negative predictor of persistence. CONCLUSIONS:
Prescription and persistence patterns in France and Spain show suboptimal adher-
ence to treatment guidelines and VKA therapy in both countries after both 6 and 12
months, suggesting that these AF patients remain at risk of stroke.
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OBJECTIVES: To evaluate colesevelam treatment persistence and associated
factors. METHODS: In this retrospective study, patients with hyperlipidemia (HL)
diagnosis were identified through electronic health records, who were 18 years
old, had an initial order for colesevelam between January 2004 and December 2011,
an LDL-C value within 3 months of the initial order date (baseline), and12 months
of LDL-C follow-up. Colesevelam treatment persistence was defined a priori as no
order gap 30 days. Multivariate stepwise logistic regression was performed to
assess clinical and patient-level factors associated with 12 months of co-
lesevelam treatment persistence. Adjusted odds ratios (OR) and corresponding 95%
confidence intervals (CIs) were calculated. A p-value 0.05 was considered statis-
tically significant. RESULTS: A total of 971 patients met the predefined inclusion
criteria, of which 48.2% had12 months of persistent treatment. Multivariate anal-
ysis showed that female sex (OR: 0.68; 95% CI: 0.53, 0.88; p0.004) and concurrent
insulin therapy (0.65; 0.46, 0.94; p0.021) were associated with a lower odds of
having 12 months colesevelam treatment persistence, whereas an increased
number of concomitant medications (1.09; 1.01, 1.19; p0.023) and concurrent in-
testinal cholesterol absorption inhibitor therapy (1.51; 1.08, 2.11; p0.016) was as-
sociated with a greater odds of having 12 months treatment persistence.
CONCLUSIONS: Several factors were significantly associated with colesevelam
treatment persistence among patients with HL in an integrated health system. In
particular, concomitant medication was associated with better treatment persis-
tence; these data may assist in optimizing therapy regimens for lipid management.
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OBJECTIVES: Dyslipidemia is a common disease that may lead to undesired car-
diovascular outcomes. We evaluated the LDL-c lowering drug use for patients at
three levels of risk defined by ATP III guidelines. METHODS: Three cohorts were
identified according to ATP III risk classification: high riskCHD or CHD equivalent
(HR); moderate risk2 risk factors (MR); low risk0-1 risk factor (LRIt’s recom-
mended that patient with these risk levels should receive the treatment if LDL was
greater than 130, 160 and 190 mg/dL, respectively. All patients were required to
have 6-month continuous health insurance coverage as ascertainment period and
LDL lowering drug use was evaluated in the subsequent two years using the US
Impact insurance claims database. RESULTS: We identified 9,866 HR, 17,539 MR
and 14,975 LR patients from 2006 to 2008. Compared with LR patients during
6-month baseline, HR and MR patients were older (mean age of 59, 59 versus 49
years), visited a cardiologist more often (46.9%, 12.2% vs 4.5%), had more hyperten-
sion (80.0%, 90.8% vs 10.8%) and diabetes (19.3%, 14.6% vs 4.6%), and incurred
higher mean health care expenditures ($8,803, $3,419 vs $1,966). For all three co-
horts, the majority of patients did not have lipid lowering medications dispensed
within 2 years (57.1%, 54.4% and 58.2%, respectively). For patients who did, lower
dose statins was the most commonly dispensed (52.0%, 52.6% and 51.4%, respec-
tively). Overall, the medication possession rate is low (0.6) and a relatively low
percentage of patients changed their medications. CONCLUSIONS: Despite ATP
recommendations for treatment, the majority of the patients at all risk levels were
not using lipid lowering medications two years after ascertainment of excess LDL
level. Among patients who obtained the medications, lower dose statins were most
commonly used. Furthermore, medication adherence in the treated patients was
suboptimal, suggesting remaining unmet therapeutic needs in this patient popu-
lation.
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OBJECTIVES: Reaching target dose of neurohormonal blockade drugs is crucial for
health outcomes in chronic heart failure (CHF). Our aim was to present dosage
analysis for CHF therapies. Our calculation was presented on the basis of represen-
tative patient attendance data from the National Health Insurance Fund Adminis-
tration (NHIFA) in Hungary.METHODS:NHIFA database uniquely contains detailed
provision data (medicine, out- and inpatient services) from the whole Hungarian
population of 10 million. All financed health care providers use the same report
structure and reported data are strictly validated. Our retrospective analyses in-
cluded data of 2004-2010 for all patients with chronic heart failure (ICD code I50) as
main diagnosis. Rate of therapy and dosage pattern were analysed on the basis of
prescription data. Real world dose of therapy was estimated as filled volume per
time between prescription fill. Estimated dose per day was aggregated on half year
basis from the first medicine record. On the basis of histological data titration
patterns were analysed as well. RESULTS: Merely 80% of CHF patients is treated
with adequate therapy. Results for dosage patterns showed, that patients are not
reaching target dose in practice, and titration process is suboptimal as well.
CONCLUSIONS: Patient and disease management program of CHF patients could
improve health outcomes by enhance treatment effectiveness.
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OBJECTIVES: Statins are the treatment of choice for lowering LDL-C levels and
reducing cardiovascular events. Statins are given to people with at least 20% risk of
having a major vascular event within 10 years. They reduce risk of serious vascular
events by 21 percent. Currently available statins in Slovakia are lovastatin, simva-
statin, fluvastatin, atorvastatin, rosuvastatin. METHODS: Data were abstracted
from Slovak Institute for Drug Control. Key data for analysis including the number
of medicine packages and financial expenditures are provided to SIDC by
wholesalers. RESULTS: The highest consumption of statins within years 2008-2012
was observed in 2010 with total expenditures of 25.9 mil. € and with 3.5 prescribed
packages. Financial expenditures rose gradually from 22.9 mil. € in 2008 to 25.9 mil.
€ in 2010 and subsequently declined to 25.3 mil. € in 2011. In first quartal of 2012 the
downward trend continues with estimated annual decrease to 22.9 millions €.
Consumption expressed in number of packages flactuated from 2.8 mil. in 2008 to
3.3 in 2011, with expected downturn to 3.1 in 2012. Significant increase in number
of issued packages was noted between 2008 and 2009, while financial expenditures
exceeded their growth between 2009 and 2010. The most frequently used statin in
Slovakia is atorvastatin (65% in 2011) followed by simvastatin (21% in 2011). The
expenditures of rosuvastatin almost trippled in both financial and physical units
within 2008-2011. The Lowest consumption showed lovastatin (0.9% in 2011).
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